Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial

Por Wynne, Chris, Schwabe, Christian, Vincent, Emmanuelle, Schueler, Armin, Ryding, Janka, Ullmann, Martin, Ghori, Vishal, Kanceva, Radmila, Stahl, Michael
Publicado no Pharmacol Res Perspect (2020)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

Por Lebbé, Celeste, Dutriaux, Caroline, Lesimple, Thierry, Kruit, Willem, Kerger, Joseph, Thomas, Luc, Guillot, Bernard, de Braud, Filippo, Garbe, Claus, Grob, Jean-Jacques, Loquai, Carmen, Ferraresi, Virginia, Robert, Caroline, Vasey, Paul, Conry, Robert, Isaacs, Richard, Espinosa, Enrique, Schueler, Armin, Massimini, Giorgio, Dréno, Brigitte
Publicado no Cancers (Basel) (2020)